Expert Interview
A discussion of the KRAS G12C NSCLC landscape, including commercial assets and the AACR data updates from GDC-6036, LY3537982, and IBI351.
Ticker(s): AMGN, MRTX, RVMD, LLY, RHHBFInstitution: UC San Diego Health
- Professor of Medicine & Lung Cancer Unit Leader at Moores Cancer Center, UC San Diego.
- Manages 250+ patients with lung cancer.
- Clinical practice and research focuses on lung cancer with a specific interest in cancer relating to females and non-smokers; active in numerous clinical trials.
Roughly how many NSCLC KRAS G12C patients do you see?
Added By: wilson_adminHow do you view Lumakras vs Krazati?
Added By: wilson_adminWhat is your impression of developmental drugs in KRAS G12C NSCLC
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
